Cite
HARVARD Citation
Pivonello, R. et al. (2020). Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet. 8 (9), pp. 748-761. [Online].